期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到71,126篇文章
< 1 2 … 250 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Introduction and impact of the young breast cancer in China consensus 认领 引用 被引量：1
1
作者 Xin Yang Chao Dong Qiang Liu 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第1期8-14,共7页
Introduction,Breast cancer is the most common cancer type in adolescents and young adults<40 years of age,accounting for 30%of cancers in this age group1.Breast cancer in the young presents significant challenges f... Introduction,Breast cancer is the most common cancer type in adolescents and young adults<40 years of age,accounting for 30%of cancers in this age group1.Breast cancer in the young presents significant challenges for patients and society,including more aggressive tumor biology,poor prognosis,genetic susceptibility,fertility preservation,and complex psychosocial issues.Moreover,because of the markedly younger median age of breast cancer,the proportion of young breast cancer patients in China is significantly higher than Western countries2.The first Young Breast Cancer in China(YBCC)consensus meeting was held in Guangzhou,China in December 2021 to address exclusive challenges and requirements facing young patients with breast cancer.Chinese medical experts from multiple specialties had an extensive discussion and formulated a consensus over several hot topics in young patients with breast cancer.The“Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer in China(2022 edition)”published in the Chinese Medical Journal has garnered significant attention3,highlighting enormous interest in the YBCC consensus in the medical community and public. 展开更多
关键词 consensus breast cancerthe diagnosis breast cancer China challenges young breast cancer treatment
暂未订购 下载PDF
Precision immunotherapy for breast cancer: from biomarkers to clinical practice 认领 引用
2
作者 Jie Mei Kai Yang +2 位作者 Xinkang Zhang Xiang Huang Yongmei Yin 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第3期320-326,共7页
The landscape of breast cancer treatment has undergone a transformative shift with the integration of immunotherapy.Historically considered a“cold”tumor with limited immunogenicity,breast cancer management was domin... The landscape of breast cancer treatment has undergone a transformative shift with the integration of immunotherapy.Historically considered a“cold”tumor with limited immunogenicity,breast cancer management was dominated by surgery,chemotherapy,radiotherapy,and targeted therapies1.However,the advent of immune checkpoint inhibitors(ICIs)has challenged this paradigm,opening a new frontier.The initial breakthrough in triple-negative breast cancer(TNBC)demonstrated that a subset of patients could derive profound and durable clinical benefit from pembrolizumab and atezolizumab2,3.Today,precision immunotherapy aims to identify the patients most likely to respond,to convert immunologically silent tumors into responsive tumors,and to strategically combine immunotherapies with other modalities to overcome resistance.This evolution from empirical application to biomarker-driven strategies marks the critical juncture at which we stand,transitioning promising clinical trial data into refined,effective,and accessible clinical practice4.Recent key clinical studies on breast cancer immunotherapy are summarized in Table 1. 展开更多
关键词 clinical practice immune checkpoint inhibitors icis targeted therapies howeverthe breast cancer precision immunotherapy biomarkers triple negative breast cancer immune checkpoint inhibitors
暂未订购 下载PDF
Tumour-Derived sEVs Promote Triple-Negative Breast Cancer Progression Associated with HAVCR2 Upregulation in Macrophages 认领 引用
3
作者 Jia Liu Binqian Wang +11 位作者 Yannan Jin Wenquan Chen Ruohan Shi Weijia Wang Xiaojing Zhang Yi Tan Zhongran Man Bo Hu Lisen Zhu Biao Zhang Chongchan Bao Gongsheng Jin 《Oncology Research》 SCIE 2026年第8期401-422,共22页
Backgrounds:Triple-negative breast cancer(TNBC)is the most aggressive breast cancer subtype with a unique tumor microenvironment,and while Programmed cell death protein 1/Programmed cell death ligand 1(PD-1/PD-L1)bloc... Backgrounds:Triple-negative breast cancer(TNBC)is the most aggressive breast cancer subtype with a unique tumor microenvironment,and while Programmed cell death protein 1/Programmed cell death ligand 1(PD-1/PD-L1)blockade represents a standard immunotherapy,most patients develop primary or acquired resistance,with few alternative immunotherapeutic targets currently available.Therefore,we aimed to identify potential immune checkpoint-related molecules involved in TNBC-macrophage crosstalk,clarify the underlying molecular mechanism mediated by small extracellular vesicles(sEVs),and provide a theoretical basis for the future development of novel immunotherapeutic targets against TNBC.Methods:Single-cell RNA-sequencing(scRNA-seq)datasets for various breast cancer subtypes were used.Pseudotime trajectory,cell-cell communication and Tumor Immune Estimation Resource 2.0(TIMER2)analyses were conducted to characterize the tumour microenvironment(TME).Immunochemistry and immunofluorescence were used to confirm the results of the above analyses.Single-nucleus RNA sequencing(snRNA-seq)was conducted on three pairs of TNBC tumour and adjacent normal tissues.The functions of tumour-associated macrophages(TAMs)and sEVs in TNBC metastasis were explored byWestern blotting,flow cytometry and cell-based experiments.Results:A total of nearly 60,000 high-quality single cells were subjected to scRNA-seq analysis,from which seven major cell types were identified.An overall increase in immune cell proportion was observed in TNBC compared with other subtypes,with the immune cell fraction in TNBC tissues being~1.8-fold higher than that in luminal A/HER2+subtypes(p<0.001).Cell-cell communication analysis indicated that TNBC cells mainly interact with macrophages.Interestingly,HAVCR2,an immune checkpoint,is expressed mainly in macrophages in the TNBC TME.HAVCR2 is associated with macrophage pseudotime progression in TNBC,which was validated by immunofluorescence staining.Moreover,analysis of The Cancer Genome Atlas(TCGA)bulk RNA-seq data revealed that HAVCR2 expression is significantly correlated with M2-like macrophage gene signatures and computationally inferred macrophage infiltration levels in TNBC,and this tissue-level transcriptional correlation is associated with poor patient prognosis.Notably,bulk RNA-seq data cannot define discrete cell subsets,and the identification of HAVCR2+M2 macrophage subsets was independently validated by scRNA-seq and snRNA-seq at the single-cell level.Furthermore,treatment with TNBC-derived sEVs is associated with concurrent increases in the expression of HAVCR2 and M2-associated markers(CD163,CD206)in macrophages.These findings reflect a correlative association rather than a demonstrated causal or regulatory relationship between HAVCR2 and M2-associated marker upregulation.Conclusion:sEVs derived from TNBC cells are associated with the upregulation of M2-associated markers and concomitant HAVCR2 upregulation in macrophages,both of which correlate with TNBC progression and metastasis.We propose that HAVCR2 may serve as a candidate prognostic marker associated with M2-like macrophage features in TNBC,and these foundational in vitro findings from Human acute monocytic leukemia cell line(THP-1)macrophages warrant further validation in primary human monocyte-derived macrophages and in vivo TNBC models. 展开更多
关键词 Breast cancer triple-negative breast cancer tumour microenvironment HAVCR2 sEVs M2-associated marker
暂未订购 下载PDF
Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2−Metastatic Breast Cancer in Japan:A Single-Center Retrospective Study 认领 引用
4
作者 Keiko Yanagihara Masato Yoshida +4 位作者 Kensaku Awaji Tamami Yamakawa Sena Kato Miki Tamura Koji Nagata 《Oncology Research》 SCIE 2026年第1期222-236,共15页
Background:Cyclin-dependent kinase 4/6(CDK4/6)inhibitors have transformed the management of hormone receptor–positive/HER2–negative(HR+/HER2–)advanced breast cancer,yet evidence for elderly or poor-performance pati... Background:Cyclin-dependent kinase 4/6(CDK4/6)inhibitors have transformed the management of hormone receptor–positive/HER2–negative(HR+/HER2–)advanced breast cancer,yet evidence for elderly or poor-performance patients remains limited.This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients,with additional subgroup analyses by age and performance status.Methods:We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2−breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025.The primary endpoint was progression-free survival(PFS).Secondary endpoints included overall response rate(ORR),disease control rate(DCR),and safety.Subgroup analyses were performed by age(<70 vs.≥70 years)and performance status(PS;0–1 vs.2–3).Results:The median PFS was 26.6 months(range,1.4–69.5).Stratified by age,median PFS was 26.9 months in patients<70 years and 26.2 months in those≥70 years(p=0.760).By PS,PFS was 26.9 months for PS 0–1 and 17.8 months for PS 2–3(p=0.099).ORR was 60.9%and DCR 93.5%;notably,all PS 2–3 patients achieved disease control.Hematologic toxicities were common,with neutropenia(80.4%)and leukopenia(86.7%)predominating,but grade≥3 anemia was rare(2.2%).Elderly patients experienced anemia more frequently,while overall toxicity remained manageable.Dose reductions occurred in 47.8%without loss of efficacy.Conclusions:In routine Japanese practice,palbociclib plus ET provided prolonged PFS and high disease control consistent with pivotal trials and international real-world evidence.Importantly,elderly patients tolerated treatment well,and selected PS 2–3 patients also derived clinical benefit.These findings indicate that neither age nor PS alone should preclude the use of palbociclib in carefully monitored real-world patients. 展开更多
关键词 Metastatic breast cancer cyclin-dependent kinase 4/6(CDK4/6)inhibitors real-world evidence hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer
暂未订购 下载PDF
Turmoil and breakthroughs:Highlights and growing pains in breast cancer therapy 2025-2026 认领 引用
5
作者 Mingxia Jiang Binghe Xu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2026年第3期295-297,共3页
Multidimensional breakthroughs reshaping treatment paradigm In 2025-2026,the most striking advances in breast cancer treatment center on the synergistic interplay between antibody-drug conjugates(ADCs)and refined mole... Multidimensional breakthroughs reshaping treatment paradigm In 2025-2026,the most striking advances in breast cancer treatment center on the synergistic interplay between antibody-drug conjugates(ADCs)and refined molecular stratification.In the human epidermal growth factor receptor 2-positive(HER2+)arena,trastuzumab deruxtecan(T-DXd)continues to cement its cornerstone role:the DESTINY-Breast05 trial showed that adjuvant TDXd reduced the hazard ratio(HR)for invasive diseasefree survival(iDFS)to 0.47 in high-risk early HER2+disease,while DESTINY-Breast09 lowered the HR for progression-free survival(PFS)to 0.56 in first-line metastatic HER2+disease. 展开更多
关键词 treatment paradigm multidimensional breakthroughs refined molecular stratificationin turmoil breast cancer antibody drug conjugates breakthroughs breast cancer therapy
暂未订购 下载PDF
Magnetic resonance imaging as a non-invasive breast cancer tool-the relevance of breast edema score:A retrospective study 认领 引用
6
作者 Anna Vasilska Silvia Tsvetkova +4 位作者 Katya Doykova Lyubomir Chervenkov Tsvetelina Velikova Margarita Vasilska Sara Sariyan 《World Journal of Radiology》 2026年第4期34-44,共11页
BACKGROUND Breast magnetic resonance imaging(MRI)provides valuable information for tumor detection,as well as potential applications in molecular characterization and prognostication.A key feature detectable on MRI is... BACKGROUND Breast magnetic resonance imaging(MRI)provides valuable information for tumor detection,as well as potential applications in molecular characterization and prognostication.A key feature detectable on MRI is the presence of breast edema,which has been associated with tumor aggressiveness and poorer clinical outcomes.AIM To determine the correlation between intramammary edema patterns as observed on breast MRI and the histopathological and molecular characteristics of the tumor.METHODS In this retrospective single-center study,123 women with biopsy-proven breast cancer underwent preoperative breast MRI from June 2022 to June 2025.The classification of edema was determined on T2-weighted images,divided into four breast edema score(BES)categories:BES-1(no edema),BES-2(peritumoral edema),BES-3(prepectoral edema),and BES-4(subcutaneous edema).The MRI findings were correlated with histological type,molecular subtype,receptor status,Ki67 index,and lymph node involvement.Data analysis was conducted using IBM SPSS Statistics for Windows,version 28.RESULTS Edema was observed in 45.5%of patients.Statistically significant correlation was observed between BES and molecular subtypes(P<0.001),hormone receptor status(P<0.001),and human epidermal growth factor receptor 2 expression(P<0.001).Higher BES categories(BES 2-4)exhibited a higher prevalence in human epidermal growth factor receptor 2-positive and triple-negative tumors,while the absence of edema(BES-1)demonstrated a predominance in hormone receptor-positive subtypes.CONCLUSION The presence and severity of MRI-based breast edema score have been found to correlate with aggressive molecular subtypes,underscoring the potential role of BES in prognostic stratification and guiding tailored treatment strategies. 展开更多
关键词 Breast magnetic resonance imaging Breast cancer Intramammary edema Breast edema score T2-weighted imaging Molecular subtype Hormone receptor status Human epidermal growth factor receptor 2 expression Ki-67 proliferation index Prognostic imaging biomarker
暂未订购 下载PDF
Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide 认领 引用
7
作者 Michael Gnant 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第3期314-319,共6页
Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of ... Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of international guidelines,regional adaptations,and the rapidly evolving fields of precision medicine and artificial intelligence(AI). 展开更多
关键词 breast cancer care regional nuances clinical research guidelines artificial intelligence ai precision medicine breast cancer global standards
暂未订购 下载PDF
Artificial intelligence empowering precision diagnosis and treatment of breast cancer:advancing global clinical practice with regional insights 认领 引用
8
作者 Zefei Jiang 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第3期311-313,共3页
Breast cancer stands as the most prevalent malignancy among women worldwide and a leading cause of cancer-related mortality,posing a persistent challenge to global public health1.In recent decades,the landscape of bre... Breast cancer stands as the most prevalent malignancy among women worldwide and a leading cause of cancer-related mortality,posing a persistent challenge to global public health1.In recent decades,the landscape of breast cancer care has been profoundly reshaped by the rapid development of precision medicine,targeted therapy,immunotherapy,and clinical translational research. 展开更多
关键词 clinical translational research clinicaltranslationalresearch targetedtherapy immunotherapy precision medicinetargeted therapyimmunotherapyand breast cancer breastcancer precisionmedicine
暂未订购 下载PDF
Adenoid Cystic Carcinoma of the Breast:Clinicopathological Features and Long-Term Outcomes from a 20-Year Retrospective Cohort 认领 引用
9
作者 Iseult M.Browne Susanna Slater +9 位作者 Myrto Kastrisiou Mae Alghawas Edward Phillips Mark Beresford Stephen R.D.Johnston Zoe Kemp Emma Kipps Marina Parton NicholasC.Turner Alicia F.C.Okines 《Oncology Research》 SCIE 2026年第9期514-528,共15页
Background:Adenoid cystic carcinoma(ACC)of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer(TNBC).Optimal management remains und... Background:Adenoid cystic carcinoma(ACC)of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer(TNBC).Optimal management remains undefined due to limited prospective data.This study aimed to characterise the clinicopathological features,treatment patterns,and long-term outcomes of breast ACC at a high-volume specialist centre,contributing real-world evidence to inform management in the absence of prospective trial data.Methods:A single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and 2020.Clinicopathological and outcome data were analysed descriptively;overall survival(OS),disease-specific survival(DSS),and relapse-free survival(RFS)were estimated using the Kaplan-Meier method.Results:Median age was 57 years.Nodal involvement was rare(8%).Adjuvant radiotherapy was administered in 88%of patients;only two patients(8%)received chemotherapy for breast ACC.Five patients(21%)experienced disease relapse after a median of 2.3 years(range 1.3-14.0).The estimated 5-and 10-year OS were both 88.4%(95%CI 74.5-100%)and DSS were both 93.3%(95%CI 81.5-100%).Conclusions:To our knowledge this represents the largest single-institution cohort study of breast ACC reported to date.The clinical behaviour of breast ACC more closely resembles salivary gland ACC than conventional TNBC,supporting a conservative locoregionally focused management approach and questioning the routine use of chemotherapy on the basis of triple-negative receptor status alone.The propensity for late relapse supports long-term surveillance beyond the standard 5-year window. 展开更多
关键词 Adenoid cystic carcinoma breast cancer triple-negative breast cancer retrospective study locoregional therapy rare breast tumour
暂未订购 下载PDF
Impact of pre-neoadjuvant radioactive iodine seed marking on pathologic complete response and survival in early-stage breast cancer patients 认领 引用
10
作者 Yihao Geng Qi Zhang +6 位作者 Zhao Bi Zhiqiang Shi Qiuchen Zhao Xiaowei Qi Rongrong Zhao Yongsheng Wang Pengfei Qiu 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第1期78-85,共8页
Neoadjuvant therapy(NAT)has become the standard treatment for patients with locally advanced breast cancer and stage II-III HER2-positive(HER2+)or triple-negative breast cancer(TNBC)1,2.It is essential to accurately m... Neoadjuvant therapy(NAT)has become the standard treatment for patients with locally advanced breast cancer and stage II-III HER2-positive(HER2+)or triple-negative breast cancer(TNBC)1,2.It is essential to accurately mark the primary breast tumor and positive axillary lymph nodes(ALNs)prior to NAT to ensure precise surgical excision,guide axillary downstaging,and guarantee reliable lesion retrieval for pathologic evaluation3.The false-negative rate of sentinel lymph node biopsy(SLNB)after NAT can be reduced to<10%by applying modalities,such as the identification of≥3 sentinel lymph nodes(SLNs)with dual-mapping techniques or removal of the marked lymph node with target axillary dissection(TAD)according to the ASCO,NCCN,and CBCS guidelines3-5.However,there is a lack of consensus regarding the optimal methods and materials for accurate marking6,7.Conventional techniques include clip placement,guidewire localization,and carbon or ink tattooing,whereas wireless technologies,such as MagseedR,radiofrequency identification tags,SAVI SCOUTR,and radioactive iodine-125(125I)seeds,have also been adopted.Traditional marking techniques have a localization failure rate of approximately 10%.In contrast,the use of 125I seeds(with a radiation dose of 0.1-0.3 mCi)has significantly improved localization accuracy8,9.Nevertheless,owing to radioactive properties,concerns have been raised regarding the potential impact of 125I seed marking on assessing the pathologic complete response(pCR)after NAT10.Moreover,whether the influence of 125I seed marking on pCR could lead to suboptimal adjuvant treatment decisions and potentially compromise long-term oncologic outcomes has not been established.To investigate the potential impact of 125I seed placement on the pCR rate and long-term outcomes in breast cancer patients receiving NAT,we conducted a retrospective cohort study utilizing propensity score matching(PSM). 展开更多
关键词 surgical excisionguide breast tumor lesion retrieval neoadjuvant therapy nat sentinel lymph node biopsy slnb breast cancer pre neoadjuvant radioactive iodine seed marking pathologic evaluation
暂未订购 下载PDF
Targeting SRC/STAT3 Signaling Impairs Cancer Stem Cell Activity by Downregulation of Hexokinase-2 in Radioresistant Triple-Negative Breast Cancer Cells 认领 引用 被引量：1
11
作者 Yu-Hao Huang Yu-Ci Tu +5 位作者 Peng-Ju Chien An-Jie Lee Chia-Liang Lin Shao-Ti Li Yueh-Chun Lee Wen-Wei Chang 《Oncology Research》 SCIE 2026年第5期584-601,共18页
Background:Triple-negative breast cancer(TNBC)is an aggressive subtype with poor prognosis and resistance to conventional therapies,including radiotherapy.Cancer stem cells(CSCs)drive tumor initiation,metastasis,and t... Background:Triple-negative breast cancer(TNBC)is an aggressive subtype with poor prognosis and resistance to conventional therapies,including radiotherapy.Cancer stem cells(CSCs)drive tumor initiation,metastasis,and therapy resistance in TNBC.Identifying pathways sustaining CSCs in radioresistant TNBC is key for targeted therapies.This study examines SRC proto-oncogene(SRC)and the signal transducer and activator of transcription 3(STAT3)activation in radioresistance and CSC maintenance.Methods:A radioresistant MDA-MB-231 TNBC cell line(231RR)was developed and compared to the parental line for CSC activity and self-renewal.Western blotting assessed molecular changes;functional assays followed SRC and STAT3 inhibitor treatment.SRCY530F overexpression and hexokinase-2(HK2)knockdown evaluated roles in CSC activity and signaling.Pathways were analyzed via metabolic assays,The Cancer Genome Atlas(TCGA)breast cancer datasets,and Harmonizome gene sets.Results:231RR cells exhibited enhanced CSC traits and upregulated SRC/STAT3 signaling,with heightened sensitivity to SRC/STAT3 inhibitors.Forced expression of SRCY530F in parental cells boosted STAT3 activation and CSC activity.SRC/STAT3 inhibition reduced HK2 without impairing glycolysis.HK2 knockdown decreased MYC proto-oncogene(c-MYC)and octamer-binding transcription factor-4(OCT4).Finally,the suppression of epidermal growth factor receptor(EGFR)activation by gefitinib resulted in the inhibition of the SRC/STAT3/HK2 axis.TCGA data linked SRC to glycolytic signatures in breast cancer.Conclusions:The EGFR/SRC/STAT3/HK2 axis drives radioresistance and CSC maintenance in TNBC via HK2 upregulation.HK2 promotes stemness mainly through non-metabolic means,not broad metabolic shifts.Targeting this pathway could overcome radioresistance and enhance TNBC outcomes. 展开更多
关键词 Triple-negative breast cancer radioresistance cancer stem cells SRC signal transducer and activator of transcription 3(STAT3) Hexokinase-2(HK2)
暂未订购 下载PDF
Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer:Advancing Targeted Therapeutic Strategies 认领 引用 被引量：1
12
作者 Mohsina Patwekar Faheem Patwekar +3 位作者 Zulhisyam Abdul Kari Muhammad Rajaei Ahmad Mohd Zain Arifullah Mohammed Rohit Sharma 《Oncology Research》 SCIE 2026年第4期356-380,共25页
Breast cancer remains the primary cause of cancer-related mortality for women globally;therefore,further breakthroughs in treatment approaches are crucial.Palbociclib,ribociclib,and abemaciclib are among the Cyclin-de... Breast cancer remains the primary cause of cancer-related mortality for women globally;therefore,further breakthroughs in treatment approaches are crucial.Palbociclib,ribociclib,and abemaciclib are among the Cyclin-dependent kinase 4 and 6(CDK4/6)inhibitors that have become an innovative family of targeted therapy for hormone receptor-positive,Human Epidermal Growth factor receptor 2(HR+/HER2-)breast cancer.These inhibitors work by preventing the action of CDK4/6,which are crucial in the regulation of the cell cycle.Leading cancer cells to cell cycle arrest and undergo apoptosis.When these inhibitors are used with endocrine medicines like letrozole and fulvestrant,clinical trials lead positive impact in progression-free survival and,in a few cases,complete survival.However,despite their effectiveness,resistance mechanisms are primary and current acquired problems,requiring combined approaches with additional targeted medicines and continuous investigation into innovative therapeutic plans.To maintain patient compliance and quality of life,common side effects such as tiredness,gastrointestinal problems,and neutropenia need to be effectively managed.There is hopefulness for wider oncological applications as next-generation CDK inhibitor development and adaptive clinical trials continue to test their potential beyond breast cancer.CDK4/6 inhibitors continue to be a key part of breast cancer treatment as cancer biology advances,marking a major advancement towards more potent and customized cancer medicines.This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2-breast cancer,highlighting their mechanisms,interaction with endocrine resistance,combination strategies,and emerging biomarkers guiding personalized therapy. 展开更多
关键词 Cyclin-dependent kinase 4/6(CDK4/6)inhibitors breast cancer targeted therapy endocrine therapy resistance mechanisms combination treatments
暂未订购 下载PDF
Self-propelled biomotors co-deliver doxorubicin liposomes and aPD-1 antibody to fight breast cancer 认领 引用
13
作者 Jia Wang Yunxiu Fan +9 位作者 Shilin Xu Zhouxue Wu Tian Hu Yun Lu Yue Li Kang Xiong Hongjun Deng Jingrong Huang Bo Yang Shaozhi Fu 《Chinese Chemical Letters》 SCIE CAS CSCD 2026年第2期375-378,共4页
Although the combination of chemotherapy and immunotherapy can improve the treatment of breast cancer,traditional drugs are highly toxic because they do not specifically target tumors.In this study,we developed a self... Although the combination of chemotherapy and immunotherapy can improve the treatment of breast cancer,traditional drugs are highly toxic because they do not specifically target tumors.In this study,we developed a self-driving bacteriaanoparticle biohybrid called Bif@PDA-aPD1/DOX-Lip by attaching polydopamine(PDA)coated doxorubicin(DOX)liposomes and the immune checkpoint inhibitor anti-programmed cell death protein 1 antibody(aPD-1)to Bifidobacterium infantis(B.infantis,Bif).Using the homing abilities of bacteria,Bif@PDA-aPD1/DOX-Lip could actively accumulate in tumor tissue,releasing DOX and aPD-1 in the acidic environment to have a synergistic anti-tumor effect.Results show that the concentration of DOX in tumors of the Bif@PDA-aPD1/DOX-Lip group was 6.31 times higher than in the free DOX group.The combination of DOX and aPD-1 not only killed tumor cells but also promoted immune normalization by maturing dendritic cells(DCs),increasing M1 macrophage ratio,and enhancing infiltration of CD8+ and CD4+T cells in tumors and spleen.Therefore,Bif@PDA-aPD1/DOX-Lip therapy significantly inhibited tumor growth and increased the average survival time of mice to over 80 days.The Bif@PDA-aPD1/DOX-Lip biomotors offer a highly effective method for enhancing chemo-immunotherapy in solid tumors. 展开更多
关键词 Anaerobic bacteria Liposome Doxorubicin Anti-PD-1 antibody Chemo-immunotherapy Breast cancer
暂未订购 下载PDF
Global patterns,temporal trends and socioeconomic inequalities in the burden of breast cancer:a population-based study across 185 countries 认领 引用
14
作者 Weijia Kong Hengna Lin +3 位作者 Jie Li Yaxiong Nie Rongshou Zheng Di Liang 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第7期1016-1030,共15页
Objective:Breast cancer is the most frequently diagnosed cancer among women worldwide and is a leading cause of cancer-related deaths.Comparative assessments of breast cancer lifetime risks across populations are limi... Objective:Breast cancer is the most frequently diagnosed cancer among women worldwide and is a leading cause of cancer-related deaths.Comparative assessments of breast cancer lifetime risks across populations are limited.This study estimated the global,regional,and national lifetime risks,temporal trends,and socioeconomic inequalities in the burden of breast cancer.Methods:Using incidence and mortality data from GLOBOCAN 2022(185 countries)and United Nations population and all-cause death data,lifetime risks were calculated using the adjusted for multiple primaries(AMP)method,which could adjust for multiple primary cancers,competing risks of other causes death,and life expectancy.Longitudinal data of breast cancer incidence from 2003±2017 were retrieved from the Cancer Incidence in Five Continents(CI5)Plus database.The temporal trends for breast cancer deaths were abstracted from the WHO Mortality Database.The lifetime risk of developing and dying from breast cancer were analyzed by socioeconomic characteristics,20 predefined geographic regions and menopausal status.Results:The overall worldwide lifetime risk of developing and dying from breast cancer was 5.51%(95%CI:5.50%±5.52%)and 1.82%(95%CI:1.82%±1.83%)in 2022,respectively.The estimated lifetime risks of developing breast cancer had a positive relationship with Human Development Index(HDI)levels and corresponding risks of 10.37%,4.42%,2.96%,and 2.91%in very high,high,middle,and low HDI regions,respectively.Very high HDI regions presented the highest lifetime risk of breast cancer death(2.70%),followed by low HDI(1.70%),medium HDI(1.54%),and high(1.38%)HDI regions.A significant correlation was identified between lifetime risks and health economics capacity.The lifetime risk of developing and dying from breast cancer primarily involved individuals≥55 years of age with remaining risks of 3.77%(developing)and 1.43%(dying)from 55 years to death.The proportion of lifetime risks among individuals 0±44 years of age was higher in Africa regions compared to other regions.In surveillance data from 36 countries,a significant increasing trend in the average annual percentage change(AAPC)was noted in 32 countries,which ranged from 0.17%in the United States to 5.84%in the Republic of Korea.Conclusions:Globally,an estimated 1 in 18 individuals were diagnosed with breast cancer during their lifetime and approximately 1 in 55 died from the disease in 2022.Lifetime risk of breast cancer disparities reveal the socioeconomic inequalities of breast cancer.Therefore,country-tailored intervention plans for breast cancer require prioritization within precision prevention to mitigate global breast cancer inequities and burden. 展开更多
关键词 Breast cancer lifetime risk disease burden incidence mortality
暂未订购 下载PDF
Translational selenium nanoparticles trigger apoptosis in triple-negative breast cancer cells through the MAPKs/Bcl2 pathway 认领 引用
15
作者 Binhua Zou Shuoshan Li +6 位作者 Kar-Him Luk Xiaoli Dong Nathanael Chun-Him Lai Wai-Yin Cheng Gang Liu Ka-Hing Wong Tianfeng Chen 《Bioactive Materials》 SCIE CSCD 2026年第8期495-507,共13页
Triple-negative breast cancer(TNBC)is characterized by aggressive biological behavior,including rapid post-treatment recurrence propensity,heightened metastatic dissemination,and significantly diminished survival outc... Triple-negative breast cancer(TNBC)is characterized by aggressive biological behavior,including rapid post-treatment recurrence propensity,heightened metastatic dissemination,and significantly diminished survival outcomes.These features emphasize the necessity for innovative therapeutic strategies in TNBC treatment.Herein,we developed selenium nanoparticles modified with a mushroom polysaccharide-protein complex(PTR-SeNPs)and evaluated them in vitro anti-tumor efficacy across 17 human TNBC cell lines,followed by elucidation of the mechanism underlying PTR-SeNPs-induced apoptosis.In vitro evaluation across TNBC cell models revealed that PTR-SeNPs exhibit promising anti-tumor efficacy with preferential induction of mitochondrial-dependent apoptosis,demonstrating significant cytotoxic efficacy through MAPKs/Bcl2 pathway.Notably,further conju-gation of PTR-SeNPs with anti-human MUC1 antibodies generated dual-modified nanoparticles(MUC1@PTR-SeNPs),which significantly enhanced anti-tumor activity in five TNBC cell lines with high/medium MUC1 expression.Furthermore,oral administration of MUC1@PTR-SeNPs for 30 days markedly inhibited tumor growth in mice bearing MDA-MB-468 xenografts via induction of mitochondria-mediated apoptosis.This work highlights the therapeutic potential of PTR-SeNPs against human TNBC,elucidates their molecular mechanisms,metabolic profile,and toxicity,thereby advancing this novel nano-mineral as a future treatment strategy for TNBC. 展开更多
关键词 Selenium Selenium nanoparticles Mucin 1 Triple-negative breast cancer Apoptosis Selenoprotein
Exercise suppresses breast cancer and reprograms the immune tumor microenvironment,cancer cell intrinsic features,and their interaction 认领 引用
16
作者 Graeme J.Koelwyn Sayyed Hamed Shahoei +11 位作者 Courtenay Graham Geoffrey M.Nonis Milad Vahedi Puneet Sidhu Emily J.Brown Alireza Khodadadi-Jamayran Juan Liu Elisa De Stanchina Kathryn J.Moore Jason W.Locasale Erik R.Nelson Lee W.Jones 《Journal of Sport and Health Science》 SCIE CAS CSCD 2026年第6期38-48,F0003,共11页
Background:Exercise links with improved cancer outcomes following a diagnosis of primary breast cancer but experimental evidence and molecular mechanistic interrogation from preclinical studies are limited.The purpose... Background:Exercise links with improved cancer outcomes following a diagnosis of primary breast cancer but experimental evidence and molecular mechanistic interrogation from preclinical studies are limited.The purpose of this study was to evaluate the effects,and dose-response,of exercise in mouse models of breast cancer,as well as elucidate cancer cell extrinsic and intrinsic responses.Methods:Independent in vivo modeling was used to investigate the effects of exercise across distinct breast cancer models.Unbiased transcriptomic and metabolomic analyses,alongside cellular and proteomic interrogation,were used to determine tumor microenvironment(TME)-and cancer cell-specific effects.Results:Exercise inhibited breast cancer growth and metastasis across multiple syngeneic mouse models compared to sham control.Tumor growth inhibition was independent of estrogen receptor status,and in the 4T1 model,exercise exerted non-dose-dependent effects.In the Metl model,exercise decreased TME immune cell content,particularly tumor-associated macrophages,while promoting an activated anticancer innate immune cell gene signature.Concurrent in vivo cancer cell-intrinsic effects were characterized by broad transcriptomic reprogramming including downregulation of metabolic pathways and upregulation of pathways regulating proliferation and apoptosis.Whole tumor metabolomic analyses unveiled broad shifts including decreased nicotinamide adenine dinucleotide(NAD+)and lactate,as well as availability of biosynthetic precursors.Finally,in silico analyses identified TME ligands,such as High Mobility Group Box 2(HMGB2)and Cardiotrophin-1(CTF1)as candidate drivers of downstream gene expression changes in cancer cells.Conclusion:Exercise suppresses breast cancer progression,which occurs in conjunction with broad reprogramming of immune TME-cancer processes and their interaction. 展开更多
关键词 Exercise Breast cancer Tumor microenvironment Cancer cell phenotypes
暂未订购 下载PDF
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer 认领 引用
17
作者 Yilin Chen Ye Qin +5 位作者 Man Yang Wei Li Minyi Cheng Yuhong Huang Teng Zhu Kun Wang 《Cancer Biology & Medicine》 SCIE CAS CSCD 2026年第3期343-362,共20页
Breast cancer exhibits profound biological and spatial heterogeneity,which contributes to variable responses to neoadjuvant chemotherapy(NAC)and challenges precision treatment planning.Radiomics,an emerging discipline... Breast cancer exhibits profound biological and spatial heterogeneity,which contributes to variable responses to neoadjuvant chemotherapy(NAC)and challenges precision treatment planning.Radiomics,an emerging discipline that converts standard medical images into high-dimensional quantitative data,offers a non-invasive and reproducible means to capture tumor phenotype,heterogeneity,and treatment-induced changes.This review provides a comprehensive overview of recent advances in radiomics for breast cancer NAC,emphasizing the roles in predicting a pathologic complete response(pCR),monitoring early therapeutic efficacy,and quantifying intratumoral heterogeneity.Among imaging modalities,magnetic resonance imaging(MRI)-based radiomics,particularly utilizing dynamic contrast-enhanced and diffusion-weighted sequences,demonstrates robust predictive performance for the pCR,with multi-center studies reporting area under the curve(AUC)values>0.80.Longitudinal and delta-radiomics approaches further enhance early response evaluation by tracking temporal alterations in imaging features that precede measurable morphologic regression.Radiomic assessment of tumor heterogeneity,especially in triple-negative breast cancer(TNBC),reveals strong associations with immune infiltration,metabolic reprogramming,and therapeutic resistance,providing mechanistic insight into radiomic biomarkers.Integrative multi-omics frameworks,combining radiomics with genomics,transcriptomics and pathomics,are increasingly elucidating the biological underpinnings of imaging phenotypes,improving both model interpretability and clinical relevance.Despite these advances,widespread clinical adoption of radiomics is limited by methodologic variability,lack of standardization,and insufficient external validation.Future efforts should focus on harmonized imaging protocols,explainable artificial intelligence,and prospective multi-center trials to translate radiomics into a clinically actionable tool.Collectively,radiomics represents a transformative approach for individualized response prediction and dynamic treatment optimization in precision breast cancer management(Figure 1). 展开更多
关键词 Breast cancer radiomics neoadjuvant chemotherapy deep learning pathologic complete response
暂未订购 下载PDF
Effect of taxane-based adjuvant chemotherapy on breast cancer-related lymphedema:A propensity score matching study 认领 引用
18
作者 KANG Dan YAN Huang +2 位作者 LU Qing CHEN Haibing WANG Ling 《中南大学学报（医学版）》 CAS CSCD 北大核心 2026年第2期256-265,共10页
Objective:Breast cancer-related lymphedema(BCRL)is a common complication of breast cancer treatment.Previous studies have suggested an association between BCRL and adjuvant chemotherapy;however,whether taxane-based re... Objective:Breast cancer-related lymphedema(BCRL)is a common complication of breast cancer treatment.Previous studies have suggested an association between BCRL and adjuvant chemotherapy;however,whether taxane-based regimens independently influence the risk of BCRL remains controversial due to potential confounding factors.Propensity score matching(PSM)can effectively reduce confounding bias.This study aims to investigate the association between taxane-based adjuvant chemotherapy and BCRL using PSM.Methods:This retrospective study was conducted using data from the electronic medical record system of Xiangya Third Hospital,Central South University.BCRL was diagnosed based on objective measurements of limb circumference.Taxane-based adjuvant chemotherapy was defined as chemotherapy regimens including docetaxel,paclitaxel,or albumin-bound paclitaxel.PSM was applied to control for potential confounders,followed by Logistic regression analysis in the matched cohort to evaluate the association between taxane-based chemotherapy and BCRL.Results:A total of 1494 patients were included in this study.Before PSM,taxane-based adjuvant chemotherapy was not significantly associated with BCRL(OR=0.979,95%CI 0.587 to 1.580;P=0.932).After PSM,363 matched patients were obtained,and the association remained non-significant(OR=0.959,95%CI 0.540 to 1.672;P=0.885).Conclusion:Taxane-based adjuvant chemotherapy is not an independent risk factor for BCRL,regardless of adjustment for known confounding factors.Further multicenter,prospective studies are warranted to further validate these findings. 展开更多
关键词 brreast cancer-related lymphedema edema breast cancer taxane-based adjuvant chemotherapy propensity score-matching
暂未订购 下载PDF
Self-assembled cyclodextrin-porphyrin nanoplatform for synergistic chemo-phototherapy and targeted delivery of camptothecin against breast cancer 认领 引用
19
作者 Jiaojiao Yang Shaokun Yang +10 位作者 Wei Cheng Jie Wu Haijing Qu Han Chen Zhiran Duan Yuqing Pan Ning Wang Chao Wang Jian Gao Bai Xiang Xiangdong Xue 《Chinese Chemical Letters》 SCIE CAS CSCD 2026年第4期727-733,共7页
The management of breast cancer remains clinically intractable,driven by its highly invasive behavior and limited susceptibility to conventional treatments.In this study,we engineered an innovative cyclodextrinporphyr... The management of breast cancer remains clinically intractable,driven by its highly invasive behavior and limited susceptibility to conventional treatments.In this study,we engineered an innovative cyclodextrinporphyrin co-assembled nanoplatform(CT NPs)to enable multimodal breast cancer therapy.By successfully encapsulating camptothecin(CPT)within this nanocarrier,the system(CTC NPs)achieved synergistic chemo-phototherapeutic efficacy through dual-modality action.The highly biocompatible cyclodextrin carrier significantly improved the physicochemical characteristics of CPT.In vivo studies revealed that CTC NPs effectively evaded clearance by the reticuloendothelial system,overcame the defect of premature drug leakage,and exhibited superior tumor targeting and infiltration capabilities.Under near-infrared(NIR)laser irradiation,CTC NPs can simultaneously induce localized hyperthermia and produce reactive oxygen species(ROS),thereby achieving efficient tumor ablation.In 4T1 tumor-bearing mice,CTC NPs exhibited targeted,safe,and highly potent anti-tumor efficacy,significantly suppressing both primary tumor progression(tumor suppression rate>95%)and metastatic dissemination.In summary,this integrated nanoplatform establishes a novel theranostic paradigm for synergistic chemo-phototherapy against triplenegative breast cancer(TNBC),achieving precise tumor ablation through NIR-triggered drug release and real-time imaging guidance. 展开更多
关键词 Breast cancer Drug delivery Camptothecin PDT PTT
暂未订购 下载PDF
The endosteal niche regulates breast cancer cell dormancy in bone:identification of new molecular determinants 认领 引用
20
作者 Antonio Maurizi Maria Salbini +7 位作者 Michela Ciocca Marzia Rea Giuseppe D.Tocchini-Valentini Matilde Merolle Hanna Taipaleenmäki Christina Møller Andreasen Manuela Pellegrini Anna Teti 《Bone Research》 SCIE CAS CSCD 2026年第3期902-919,共18页
Cellular dormancy compromises the long-term survival of breast cancer patients.Bone represents a frequent site for metastasis,where Spindle-shaped N-cadherin+CD45−osteoblasts(SNOs)hold dormant metastatic cells in the ... Cellular dormancy compromises the long-term survival of breast cancer patients.Bone represents a frequent site for metastasis,where Spindle-shaped N-cadherin+CD45−osteoblasts(SNOs)hold dormant metastatic cells in the endosteal niche with a Notch2-dependent mechanism.In this work,we excluded the involvement of Notch1 in SNO-induced breast cancer cellular dormancy by immunofluorescence/immunohistochemistry and molecular approaches,using breast cancer tissues and cell lines.RNAdSeq in human bone metastatic MDA-MB231 breast cancer cells sorted for Notch1HIGHand Notch2HIGHexpression demonstrated that,compared to their low counterpart,only Notch2HIGHcells expressed enriched pathways relevant for the metastatic process,including pluripotency and Hematopoietic Stem Cell(HSC)gene signatures.They expressed the HSC-associated genes CXCR4,CD34 and TIE2 and MDA-MB231 cells enriched in the encoded proteins showed lesser proliferation ability.Reduced incidence of osteolytic lesions was induced by CXCR4HIGHcells intratibially injected in immunocompromised mice,while lower lesion extension was induced by CXCR4HIGHand TIE2HIGHinjected cells compared to CXCR4LOWand TIE2LOWcells.Notch2HIGHcells were enriched in endoplasmic reticulum stress and unfolded protein response genes and overexpressed the CD177 protein,while the CD177 ligands,Plaur,Itgam and Ceacam 1,were highly expressed in SNOs.Kaplan-Meier plots showed positive correlation between high expression of CD177,ITGAM and CEACAM 1-but not PLAUR-and overall survival of patients.CD177HIGHcells were also CXCR4HIGH,CD34HIGHand Notch2HIGHand proliferated less than CD177LOWcells.These results support the relevance of Notch2 in SNOmediated cellular dormancy and identified new pathways implicated in bone metastatic breast cancer cell quiescence. 展开更多
关键词 cellular dormancy metastatic cells endosteal niche bone metastasis breast cancer molecular approachesusing
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 250 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈